A review of acetaminophen tablets, a subsidiary of Taiji Group

Taiji Group announced in the evening of February 10 that recently, Southwest Pharmaceutical, the holding subsidiary of the company, received the approval document for supplementary application for acetaminophen tablets (approval No 2020b02183) issued by the State Food and Drug Administration: after examination, the drug passed the consistency evaluation of quality and efficacy of generic drugs The data showed that paracetamol tablet was used for fever caused by common cold or influenza, and also for relieving mild to moderate pain such as headache, joint pain, toothache, etc In January 2019, Southwest Pharmaceutical submitted an application for consistency evaluation of the variety to the State Food and drug administration Up to now, Southwest Pharmaceutical has invested 3.55 million yuan (Unaudited) in R & D of the product The drug is a class a drug in the catalogue of national basic medical insurance, industrial injury insurance and maternity insurance drugs (2019 version) and a variety in the catalogue of national basic drugs (2018 version).